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Malaria is the most important parasitic disease of humans, each
year causing more than one million deaths predominantly in young
children [1]. Malaria's severe pathophysiology results from the
development of Plasmodium spp. parasites inside red blood cells
(RBCs). Compared to normal human RBCs, parasite-infected RBCs
(IRBCs) exhibit markedly altered morphological, antigenic and
functional properties, including increased membrane rigidity, re-
duced RBC deformability, the appearance of electron dense knobs onthe RBC membrane surface and the ability to adhere to vascular
endothelium (see Cooke et al., for review [2]). These parasite-induced
modiﬁcations result from the synthesis and export of numerous
parasite-encoded proteins from the intracellular parasite into the RBC
cytosol. Some of these exported proteins participate in protein
interactions with RBC membrane skeleton proteins, affecting the
structural and mechanical integrity of the IRBC, and in some cases, are
major contributors to falciparum malaria's unique virulence (see
Cooke et al., for review [2]).
The membrane skeleton of a normal human RBC consists of a
regular array of numerous proteins, with the major structural
components being αβ-spectrin heterodimers, actin and protein 4.1
(4.1R). Actin is a 43 kDa monomer protein that oligomerises to form
30–40 nm long ﬁlaments containing 12–14 monomer units which are
predominantly located at the vertices of the spectrin hexagonal array
in regions known as junctional complexes (see Walensky et al., for
review [3]). Actin participates in interactions with both spectrin and
4.1R, forming the spectrin–actin–4.1R ternary complex and the
structural backbone of the membrane skeleton. In this ternary
complex, 4.1R functions to stabilise the spectrin–actin interactions
(see Gascard and Mohandas [4] for review). To date, mapping studies
have deﬁned a 140 residue region located in the N-terminal region of
β-spectrin and a 26 residue region in 4.1R that bind actin [5,6],
however the residues in actin that bind spectrin and 4.1R are not
yet delineated. Additional protein interactions between 4.1R, the
transmembrane proteins glycophorins C and D (GPC and GPD,
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overlying plasma membrane to the underlying membrane skeleton
[7,8].
Previously, we and others have performed detailed studies to
identify the interactions of numerous exported proteins that
contribute to malaria's severe virulence with components of the
RBC skeleton, deﬁne the speciﬁc sub-domains involved and assess
their contribution to the structural and mechanical modiﬁcation of
IRBCs. Studies have shown that the Ring-infected Erythrocyte Surface
Antigen (RESA) binds to spectrin via a 48 residue region in RESA and
the repeat 16 of β-spectrin (βR16) [9,10] in an interaction that
stabilises spectrin tetramers and confers both increased thermal
stability on the IRBC membrane and offers a possible mechanism to
suppress further merozoite invasion of the RBC [10–12]. Other studies
have shown that a 19 residue region of the Mature parasite-infected
Erythrocyte Surface Antigen (MESA) binds to the 30 kDa region of
4.1R in an interaction that displaces p55 from its normal interactions
with 4.1R. Such interactions could thereby modulate the in vivo
ternary 4.1R–GPC-p55 complex, altering the stability of the IRBC's
membrane skeleton [13,14]. Recently, we have also shown that 14
residues of the P. falciparum Erythrocyte Membrane Protein 3
(PfEMP3) bind to the C-terminal EF1–2 region of α-spectrin, resulting
in destabilisation of the RBC membrane skeleton [15,16]. The Knob
Associated Histidine Rich Protein (KAHRP), which is required for the
production of knobs on the IRBC surface [17,18], binds to spectrin,
actin and ankyrin [19,20]. Recent mapping and functional studies
have shown a 72 residue region of KAHRP binds to repeat 4 of α-
spectrin (αR4) [21], a 91 residue region of KAHRP (which includes the
5′ repeat region) binds to ankyrin [20] and that the 3′ repeat region of
KAHRP (69 residues) is required for knob production [18]. KAHRP also
binds to the cytoplasmic tail (VARC region) of the major antigenic
adherence protein, P. falciparum Erythrocyte Membrane Protein 1
(PfEMP1) [22,23], which in turn can bind spectrin and actin [19,24].
Together these KAHRP–PfEMP1–membrane skeleton interactions
cluster PfEMP1 at knobs and provide the stabilizing interactions that
anchor PfEMP1 in the IRBC membrane with sufﬁcient strength to
withstand the physiological shear forces exerted by circulating blood,
allowing the IRBCs to adhere to the vascular endothelium in vivo [17].
Plasmodium falciparum Antigen 332 (Pf332) is the largest parasite
protein (approx. 700 kDa) that is exported into the IRBC cytosol
[25,26]. Pf332 is highly charged and possesses an extensive region of
highly degenerate glutamic acid-rich repeats that span over 4300
residues (Fig. 1A; [27]). The pf332 gene shares features common to
other genes that encode exported parasite proteins, including a two
exon gene structure and a P. falciparum protein trafﬁcking motif
(PEXEL or Vacuolar Transport Signal (VTS); [28,29]) encoded within
exon 1 (Fig. 1A). Pf332 is expressed in trophozoites and is trafﬁcked
through the RBC cytosol via a Brefeldin-A sensitive secretory pathway
in parasite-produced membranous structures known as Maurer's
clefts (MCs). In more mature schizont parasite stages, Pf332 is found
in association with the RBC membrane skeleton [25,26,30]. Recent
studies have implicated Pf332 in modulating IRBC membrane rigidity,
and loss of Pf332 leads to a decrease in PfEMP1 surface expression and
a corresponding decrease in IRBC adhesiveness [31,32].
In this study, we have examined the association of Pf332 with the
RBC membrane skeleton. Using a series of recombinant Pf332 fusion
proteins in in vitro protein interaction assays with either inside-out
vesicles (IOVs) formed from normal human RBCs or puriﬁed actin, we
have broadly deﬁned the RBC membrane skeleton binding region of
Pf332 to a 260 residue region located proximal to the C-terminus of
Pf332. Finer mapping studies using Triton X-100 detergent extrac-
tions of lysed and resealed RBCs incubated with Pf332 fusion proteins
mapped binding domains to 86 residue and 72 residue sub-regions.
Additional interaction assays demonstrated that Pf332 recombinant
proteins do not bind to spectrin. Rather, actin co-sedimentation assays
demonstrated that the 260 residue region of Pf332 bound in a speciﬁcand saturable manner to F-actin (Kd=0.60 µM) at a binding site not
shared with another known actin-binding malaria protein. The
continued elucidation of protein interactions at the IRBC membrane
skeleton will facilitate construction of a detailed protein interaction
model and increase our understanding of the complex structural and
mechanical modiﬁcations of IRBCs that ultimately result in the severe
clinical manifestations of P. falciparum malaria.
2. Materials and methods
2.1. Parasite culture
Plasmodium falciparum parasites (3D7 line) were cultured in vitro
and synchronized using sorbitol as previously described [33].
2.2. Construction of pMAL-c2 clones, and expression and puriﬁcation of
recombinant proteins
Speciﬁc oligonucleotide primers (Table 1) were designed with
reference to the pf332 nucleotide sequence [30,34] and used to PCR
amplify regions of pf332 from P. falciparum 3D7 genomic DNA. PCR
products were cloned into the pMAL-c2 Maltose-Binding Protein
(MBP) expression plasmid (New England Biolabs, USA) using
GATEWAY™ Cloning Technology (Invitrogen, USA) and the nucleo-
tide sequence of each clone was conﬁrmed by automated DNA
sequencing. MBP–Pf332 fusion proteins were expressed, puriﬁed,
dialysed against phosphate-buffered saline (PBS; 10 mM Na2HPO4/
NaH2PO4, pH 7.4, containing 0.15 M NaCl) and concentrated by
centrifugal ﬁltration as previously described [15]. Total protein
concentrations were determined by Bio-Rad Protein Assays (Bio-Lab
Laboratories, USA). The isoelectric points (pI) of each MBP–Pf332
fusion protein and rabbit actin were determined using http://ca.
expasy.org/tools/pi_tool.html.
2.3. In vitro binding assays using IOVs
Inside-out vesicles (IOVs) were prepared for use in binding assays
from normal human RBCs using previously described methods [15].
For the binding assays, prepared IOVs diluted in IOV Incubation Buffer
(IB; 138 mM NaCl, 5 mM KCl, 6 mM Na2HPO4, 5 mM glucose, pH9.0)
were used to coat wells of 96 well microtiter plates (Dynatech
Laboratories Inc., USA) overnight at 4 °C. Wells were then blocked
overnight at 4 °C with 5% (w/v) Bovine Serum Albumin (BSA) in IB,
before washing twice with IB. Then, 0.5–4 μg of total recombinant
MBP–Pf332 fusion protein diluted in IB containing 0.05% (v/v) Tween
20 was added to each well and incubated overnight at 4 °C. Wells
were washed 5 times with IB before proteins were stripped from the
wells using heated (70 °C) reducing sample buffer. Proteins were
resolved by SDS-PAGE in 10% (w/v) polyacrylamide gels and
transferred to Polyscreen® polyvinylidene diﬂuoride (PVDF) mem-
brane (NEN® Life Science Products Inc., USA). Interacting proteins
were detected by immunoblotting using a primary polyclonal
rabbit anti-MBP antiserum [15] and secondary anti-rabbit Ig-
horseradish peroxidase conjugate (Silenus Labs Pty. Ltd., Australia).
Autoradiographic images were obtained using NEN Renaissance™
Western Blot chemiluminescence reagent (NEN® Life Science Pro-
ducts Inc., USA).
IOVs were also prepared from 3D7 P. falciparum-IRBCs (pIOVs).
Brieﬂy, mature stage IRBCs were puriﬁed from culture by Percoll
Density Gradient Centrifugation [35]. Isolated IRBCswere then treated
identically to that described above for the preparation of IOVs from
normal human RBCs [15]. pIOVS were then resuspended in IOV
Incubation Buffer and used in immunoblots.
The speciﬁcity and saturability of the interaction between Pf332-
F19 and IOVs was demonstrated by incubating serial dilutions of
MBP–Pf332-F19 protein (titrated from 5 μM to 0.0 μM) with IOVs in
Fig. 1. Mapping the region of Pf332 that binds the RBC membrane skeleton. A. Schematic representation of full length Pf332 protein. The pf332 gene is comprised of two exons
separated by an intron [30]. Residues 1–567 are encoded by the ﬁrst exon of the pf332 gene and encodes a PEXEL motif (RSLAD), a Duffy Binding-Like domain (DBL; light shaded
region) and a predicted transmembrane spanning domain (TM). Residues 568–6098 are encoded by the second exon of the pf332 gene and encode an extensive glutamic acid-rich
region (darker shaded region). The relative locations of the twenty one fragments (F1 through F20, plus F18+19) that were expressed and puriﬁed as MBP fusion proteins and
together represent the Pf332 protein sequence encoded by the second exon of pf332 are shown below the protein schematic. Relevant amino acid residue numbers are shown
adjacent to the schematic. B. Puriﬁed MBP–Pf332 fusion proteins. 2 µg (total protein) of each puriﬁed protein was resolved by SDS-PAGE and stained with Coomassie Brilliant Blue.
The proteins are indicated by the protein fragment number above each lane. C. Each of the puriﬁed MBP–Pf332 fusion proteins (50 ng total protein) was immunoblotted with anti-
MBP antiserum to conﬁrm the presence of the N-terminal MBP tag and demonstrate the apparent molecular mass of each protein when immunoblotted. D. IOV binding assay
immunoblots. Samples stripped from IOV-coated wells (lanes headed by ‘+’) and BSA-coated wells (lanes headed by ‘−’) are indicated. The name of each Pf332 protein fragment
analysed is shown above each pair of lanes. Pf332-F19 bound to IOVs, with only residual levels observed binding to BSA. The interaction positive control protein MBP–PfEMP3-F1a
bound to IOVs and at much lower levels to BSA. MBP showed only residual binding to IOVs and did not bind to BSA. The immunoblotted assay samples, although separated into
multiple panels here, were derived under identical and simultaneous experimental conditions.
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by SDS-PAGE and transferred to PVDF and immunoblotted with anti-
MBP antiserum. The resulting autoradiographic data was analysed by
densitometry using the public domain NIH Image program (http://rsb.info.nih.gov/nih-image/). A saturation of binding curve was
constructed from the densitometric data of a representative binding
assay after subtraction of the signal obtained for the presence of
residual MBP–Pf332–F19 binding to BSA. The concentration at which
Table 1
Oligonucleotide primers sequences.
Fragment Isoelectric point (pI)a Primerb Sequence (5′→3′)c
F1 4.29 p1 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcCATTCTTTGATTGATCGTGTTC
p2 (−) ggggaccactttgtacaagaaagctgggtcgaattcAATTAATTGACCTTTAAATGTA
F2 4.00 p3 (+) ggggacactttgtacaagaaagctgggtcgaattcTTTAAAGGTCAATTAATTAACGA
p4 (−) ggggaccacagtttgtacaaaaaagcaggcttagaattcATTTTCTTTGTCTCGAACGTCA
F3 3.97 p5 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcAACGATGACGTTCGAGACAAA
p6 (−) ggggaccactttgtacaagaaagctgggtcgaattcTGCTCCTTCTTCTTCTACAACTTCC
F4 3.96 p7 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcATAGTAGAAGATGAAGCATCAGTC
p8 (−) ggggaccactttgtacaagaaagctgggtcgaattcTTCATTGTCTTCATTAATCAAACC
F5 4.05 p9 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcAAAGAAGAATTAATTACTGAAATG
p10 (−) ggggaccactttgtacaagaaagctgggtcgaattcTGGAGTATGTTCATTAATAATATC
F6 4.00 p11 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcCCATTAGAAGAAACGAAAATTG
p12 (−) ggggaccactttgtacaagaaagctgggtcgaattcGCTAACTGATCCAATATCTTT
F7 4.09 p13 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcGTTAAAGATATTGGATGAGTTAG
p14 (−) ggggaccactttgtacaagaaagctgggtcgaattcTCCTTCATACTGTACAGC
F8 3.97 p15 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcACAGAAGAAGCTGTACAGTATG
p16 (−) ggggaccactttgtacaagaaagctgggtcgaattcCGTAATCGATCCTTCTCCA
F9 4.16 p17 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcGGAGAAGGATCGATTACG
p18 (−) ggggaccactttgtacaagaaagctgggtcgaattcTACGACTTCTTCAGTTACTGTTG
F10 3.69 p19 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcGAAATAGTGGACGAAGTGTCTC
p20 (−) ggggaccactttgtacaagaaagctgggtcgaattcTTCCCCATTAACGGATTCAGA
F11 3.91 p21 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcTCTGAATCCGTTAATGGG
p22 (−) ggggaccactttgtacaagaaagctgggtcgaattcTATTTTTTCAGTAAGTGATTTTTCG
F12 3.87 p23 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcAAAGAAATAATTGACGAAAAATCAC
p24 (−) ggggaccactttgtacaagaaagctgggtcgaattcTTTCTCAATCCATACATTTTC
F13 3.84 p25 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcAATGTATGGATTGAGAAAGAA
p26 (−) ggggaccactttgtacaagaaagctgggtcgaattcTGATCCTTGTTGTACAACTTT
F14 3.80 p27 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcCAGGAAGAATCTCATGTTGAAA
p28 (−) ggggaccactttgtacaagaaagctgggtcgaattcAATATCTTCAGTAATTGATTCG
F15 3.90 p29 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcAAAATCGAATCAATTACTGAAGAT
p30 (−) ggggaccactttgtacaagaaagctgggtcgaattcAGTAAAAGATCCACCTTGTAT
F16 3.83 p31 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcGAAATAATACAAGGTGGATATT
p32 (−) ggggaccactttgtacaagaaagctgggtcgaattcATTAAAAGACCCTTCTTCTAA
F17 3.84 p33 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcGTAGAAGAAGGATCAGATACG
p34 (−) ggggaccactttgtacaagaaagctgggtcgaattcCATAATTTTATAATTAAGGGC
F18 4.38 p35 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcGATAAAGCCCTTAATGAG
p36 (−) ggggaccactttgtacaagaaagctgggtcgaattcGTCATTGGCAGATTTATTTG
F19 4.77 p37 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcAATGATACTGTAATGGTTAT
p38 (−) ggggaccactttgtacaagaaagctgggtcgaattcAAGTTCATCGTACTTAAATTG
F20 5.49 p39 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcAAATATGCTAAGAAAAGATTT
p40 (−) ggggaccactttgtacaagaaagctgggtcgaattcGTTCTCATTTACACTAAATTC
F19a 5.67 p41 (+) ccgggaaggatttcaAATGATACTGTAATGGTTATAAAAATC
p42 (−) cgggaattcATTCCTCATATCGATTTTCAAATC
F19b 4.83 p43 (+) ccgggaaggatttcaACATATGAAAGCGATCAAAATGAC
p44 (−) cgggaattcTTCCTGTAATACATTACTGACATC
F19c 4.86 p45 (+) ccgggaaggatttcaAATGCATCAGAAGCTTCTGTTG
p38 (−) ggggaccactttgtacaagaaagctgggtcgaattcAAGTTCATCGTACTTAAATTG
F18+19 4.66 p35 (+) ggggacaagtttgtacaaaaaagcaggcttagaattcGATAAAGCCCTTAATGAG
p38 (−) ggggaccactttgtacaagaaagctgggtcgaattcAAGTTCATCGTACTTAAATTG
Oligonucleotide primers sequences used in the construction of the pf332 DNA fragments.
a The isoelectric points (pI) of each MBP–Pf332 fusion protein and rabbit actin were determined using http://ca.expasy.org/tools/pi_tool.html. The pI of rabbit actin is 5.24.
b (+) and (−) refer to coding (forward) and non-coding (reverse) DNA sequences, respectively.
c Gene speciﬁc sequence shown in uppercase; non-complimentary sequence shown in lower case and enzyme restriction sites are underlined.
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analysis of the saturation of binding curve data.
2.4. In vitro binding assays using spectrin
Spectrin-binding assays were performed in a similarmanner to the
IOV binding assays, with some modiﬁcations. Brieﬂy, PBS was used
instead of IB and 100 ng of puriﬁed human spectrin (Sigma, Australia)
was used to coat the wells of a 96 well microtitre plate (Dynatech
Laboratories Inc., USA). Assays were then processed as described
above.
2.5. Triton X-100 detergent solubility
Triton X-100 (TX100) detergent extractions were performed on P.
falciparum 3D7 parasites harvested to more than 99% trophozoite
stage IRBCs by Percoll Density Gradient Centrifugation [35]. Then,45 μl of puriﬁed IRBCs was extracted in 1.5 ml PBS containing 1% (v/v)
TX100 in the presence of protease inhibitor solution (Roche
Diagnostics, Australia) for 10 min on ice. Samples were centrifuged
at 12,000×g for 5 min at 4 °C before removal of the supernatant. The
TX100 insoluble pellet was then washed in PBS/TX100/protease
inhibitor solution before resuspension of the pellet and supernatant
fractions in reducing protein sample buffer. A sample of the resultant
TX100 insoluble 3D7 parasite fraction was resolved in 0.5% (w/v)
agarose/3.0% (w/v) acrylamide gels [36] alongside samples of IOVs
(prepared from normal human RBCs), pIOVs (prepared from 3D7
P. falciparum-IRBCs) and Cross-linked SDS Molecular Weight Markers
(Sigma, Australia) using a Mini-PROTEAN® III Cell apparatus (Bio-
Rad). Samples were then transferred to PVDF membrane and
immunoblotted with rabbit polyclonal anti-Pf332 antiserum (1:300
dilution; K. Berzins, Stockholm University, Sweden).
TX100 detergent solubilities were also performed on lysed and
resealed RBCs pre-incubated with MBP–Pf332 fusion proteins, MBP
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control proteins, respectively [15]). Lysis and resealingwas performed
as previously described [15]. The resultant samples were then
resolved in 12% (w/v) polyacrylamide gels, before immunoblot
detection using polyclonal rabbit anti-MBP antiserum.
2.6. Actin co-sedimentation assays
Actin co-sedimentation assays were used to demonstrate
the speciﬁcity and saturability of the interaction between Pf332 and
F-actin, and were performed as previously described [15]. Brieﬂy,
monomeric G-actin (Cytoskeleton, Denver CO, USA; ≥95% pure by
SDS-PAGE analysis) was polymerised to F-actin. F-actin (5 μM) was
then interacted with Pf332-F19 (titrated from 5 μM to 0.0 μM)
alongside the negative interaction control proteins MBP–Pf332-F7
and MBP alone (both 5.0 μM) [15]. Pellet and supernatant fractions
were resolved proteins by SDS-PAGE in 10% (w/v) polyacrylamide
gels before transfer to PVDF for immunoblot detection using
polyclonal anti-MBP antiserum. Equal loading of pellet and superna-
tant samples was demonstrated by probing duplicate blots with
monoclonal anti-actin antibodies (Sigma, Australia). The resulting
autoradiographic data was analysed by densitometry (see above). A
saturation of binding curve was constructed from the densitometric
data obtained from a representative co-sedimentation experiment
after subtraction of the signal obtained for the presence of non-
bindingMBP–Pf332-F7 in the pellet. The half saturation concentration
(Kd) was determined by regression analysis of the saturation of
binding curve data.
Inhibition of binding to actin co-sedimentation assays were
performed to determine if the binding of either MBP–PfEMP3-F1a or
MBP–Pf332-F19 to F-actin inhibited the binding of the other to actin.
These assays were performed as described above for actin co-
sedimentation assays except that F-actin (5 μM) was added to either
MBP–PfEMP3-F1a (5 μM) or MBP–Pf332-F19 (5 μM) prior to addition
of the other protein (titrated from 5.0 to 0.0 μM) and subsequent
incubation for an hour at room temperature. Protein mixtures were
then ultracentrifuged and the resultant pellet and supernatant
fractions collected, resolved by SDS-PAGE in 10% (w/v) polyacryl-
amide gels and immunoblotted using either polyclonal anti-MBP
antiserum or monoclonal anti-actin antibodies, as described above.
Additional inhibition co-sedimentation assays were performed in
which F-actin (5 μM) was pre-incubated for 1 h with either MBP–
PfEMP3-F1a (5 μM) or MBP–Pf332-F19 (5 μM), prior to the addition
the other protein (titrated from 5.0 to 0.0 μM) and subsequent
incubation for a further hour at room temperature. Assays were then
processed and analysed as described above.
3. Results
3.1. Cloning, protein expression and puriﬁcation
The P. falciparum pf332 gene has a two exon gene structure and
encodes a PEXEL/VTS motif (RSLAD; residues 77–81) in its ﬁrst exon
[30]. Sequences encoded by the ﬁrst exon were excluded from
our analyses because current membrane topology predictions place
the N-terminal 540 residues of Pf332, which are located upstream of
the predicted transmembrane domain (Fig. 1A),within theMCsduring
trafﬁcking of Pf332 to the RBCmembrane before subsequent exposure
on the IRBC membrane surface [30]. In either of those locations, the
540 residues would be unavailable for binding to the RBC membrane
skeleton. Given the unusually large size of the pf332 second exon,
which encodes some5530 residues and is largely comprisedof a highly
repetitive glutamic acid-rich region (approx. 4300 residues; Fig. 1A), it
was not feasible to clone and express recombinant Pf332 proteins
from a full length pf332 second exon DNA fragment. Instead, deﬁned
fragments that together represent the entire second exon of the pf332gene were PCR ampliﬁed, cloned into the pMALc2 vector, sequenced
and used to express and purify MBP–Pf332 fusion proteins. The
puriﬁed MBP–Pf332 fusion proteins that were used in initial
interaction assays are shown in Fig. 1B. Immunoblot detection using
polyclonal anti-MBP antisera was performed on all puriﬁed MBP–
Pf332 fusion proteins to demonstrate the presence of the MBP tag and
conﬁrm the identity of each protein (Figs. 1C and 3C).
3.2. Mapping the Pf332 RBC membrane skeleton binding domain
Inside-out vesicles (IOVs) were prepared from normal human
RBCs and used in binding assays. A sample of prepared IOVs resolved
by SDS-PAGE and stained with Coomassie Brilliant Blue conﬁrmed the
presence of the major RBC membrane skeleton proteins, including
spectrin and actin (data not shown).
An initial series of IOV binding assays using the MBP–Pf332 fusion
proteins -F1 through -F20 mapped the general region of Pf332 that
binds to the RBC membrane skeleton. Representative immunoblots
are shown in Fig. 1C. Pf332-F19 bound to IOVs, but only residual levels
were detected binding to BSA. The positive control MBP–PfEMP3-
F1a.1, a known IOV binding protein fragment [15], also bound to IOVs,
and only minimally to BSA. MBP alone failed to bind to BSA, and only
extremely low levels were detected interacting with IOVs. These
initial interaction assays identiﬁed a 260 residue region of Pf332
encoded by the second exon of the pf332 gene as the region of Pf332
that binds to the RBC membrane skeleton.
A parallel set of assays interacted Pf332 fusion proteins with
membrane skeleton proteins maintained in the intact RBC and took
advantage of the fact that proteins linked to the RBC membrane
skeleton, including Pf332, are typically insoluble in non-ionic
detergents such as Triton X-100 (TX100; [37]) (Fig. 2B). In these
assays, resealed RBCs that had been pre-incubatedwith puriﬁedMBP–
Pf332 fusion proteins, MBP alone or with the interaction control
proteins MBP–PfEMP3-F1a or -F5 (positive and negative binding
proteins respectively; [15]) were extracted with TX100 and the
resultant TX100 soluble and insoluble fractions immunoblotted with
anti-MBP antiserum (Fig. 2C). Data from these assays conﬁrmed that
the 260 residue -F19 region of Pf332 bound to the RBC membrane
skeleton. This experiment also indicated the presence of binding
residues contained within -F18, the region that is located immediately
upstream of -F19. We also generated a -F18+19 fusion protein
(Fig. 1B and C), in which the -F18 and 19 regions were contained in
the same contiguous fusion protein, and conﬁrmed its ability to bind
to the RBC membrane skeleton (Fig. 2C).
3.3. Finer mapping of the membrane skeleton binding region of Pf332
To further deﬁne the residues within Pf332-F19 that bind to the
RBC membrane skeleton, we generated smaller non-overlapping sub-
fragment MBP fusion proteins (Fig. 3A, B and C). Representative
immunoblots of TX100 extracted resealed RBCs pre-incubated with
either -F19, -F19a, -F19b or -F19c (Fig. 3D) mapped the binding
residues of -F19 to the N-terminal 86 residues that are present in
-F19a. Downstream sequences that are located within the 72 residue
-F19c region were also observed to possess some binding to the RBC
membrane skeleton however, no bindingwas detectedwith -F19b but
this may reﬂect the relatively poor quality of the full length protein
generated rather than the lack of binding sequences in -F19b. To
demonstrate the speciﬁcity and saturability of this -F19–IOV interac-
tion, serial dilutions of MBP–Pf332-F19 were interacted with IOVs,
and the resultant immunoblot data from a representative assay was
analysed by densitometry and graphed as a saturation of binding
curve (Fig. 3D). Using regression analysis of the saturation curve
data, the half saturation concentration (Kd) was determined to be
Kd=0.40 µM.
Fig. 2. RBC membrane skeleton association of Pf332. A. Schematic representation of full length Pf332 protein showing the relative locations of the twenty one Pf332 fragments
investigated. B. Immunoblot detection of Pf332 in P. falciparum-IRBCs extracted with Triton X-100. Samples of IOVs and IOVs prepared from P. falciparum-IRBCs (pIOVs) were
resolved alongside the TX100 insoluble fraction of P. falciparum 3D7 parasites in 0.5% (w/v) agarose/3.0% (w/v) acrylamide gels [36], before transferring to PVDF membrane and
immunoblotting with anti-Pf332 antiserum. Pf332 was detected as a band of N584 kDa (indicated by the arrow) in the 3D7 TX100 insoluble fraction and in the pIOVs sample, but not
in the IOVs prepared from normal human RBCs. Although originally described as amegadalton protein [25,27], Pf332 is currently predicted to be a 700 kDa protein, andwas observed
in our hands as having a molecular mass in excess of 584 kDa. It is not uncommon for highly charged repetitive malaria proteins, such as Pf332, to resolve at anomalous higher-than-
predicted molecular masses in SDS-PAGE [47]. C. TX100 extractions were preformed on lysed and resealed RBCs that had been incubated with 5 µM puriﬁed MBP–Pf332 fusion
proteins, MBP alone, or with the binding control proteins MBP–PfEMP3 fusion proteins F1a or F5 (RBC membrane skeleton binding and non-binding regions, respectively; [15]). The
TX100 soluble (S) and insoluble (I) fractions were resolved by SDS-PAGE and immunoblotted with anti-MBP antiserum. MBP–Pf332-F19 was detected in both the soluble and
insoluble fractions. The region adjacent to -F19, -F18, was also detected in the insoluble fraction, but at lower levels than -F19. When -F18 and -F19 were combined into the same
contiguous fusion protein (-F18+19), the protein was also detected in the insoluble fraction. As expected, the RBCmembrane binding control protein MBP–PfEMP3-F1a was present
in both the soluble and insoluble fractions, whereas the non-binding MBP–PfEMP3-F5 protein and MBP alone were present only in the soluble fractions. No signiﬁcant
immunoreactivity was observed in either fraction for TX100 extracted RBCs lysed and resealed in the absence of MBP or other MBP fusion proteins. The diversity of protein sizes and
the number of bands per protein sample are reﬂective of the sizes of the Pf332 gene fragments expressed as MBP fusions, differences in their coding sequences, and the ability of
E. coli to express these gene fragments as full length proteins.
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To determine if the -F19 region of Pf332 binds to the RBC
membrane skeleton via interactions with actin, co-sedimentation
assays were performed using polymerised F-actin. Under the
sedimentation conditions used, monomeric actin (G-actin) would be
typically found in the supernatant, whereas F-actin would be located
in the pellet [15]. In these assays, -F19 bound to F-actin and was
detected in the pelleted fractions (Fig. 4A). The speciﬁcity and
saturability of the interaction between F-actin and -F19 proteins was
demonstrated by incubating constant F-actin (5.0 µM) with titrated
serial dilutions of -F19 (from 0.0 µM to 5.0 µM) or the negative control
proteins MBP–Pf332-F7 or MBP alone (5.0 µM). Immunoblots of
representative experiments are shown (Fig. 4A). Due to the polymericnature of F-actin, sensitive resonance mirror detection measurements
to determine the kinetics of the actin–MBP–Pf332-F19 interaction
were not possible. However, the kinetics of the actin–MBP–Pf332-F19
interaction could be estimated from the saturation of binding curve
for -F19 binding to F-actin (Fig. 4C). The corresponding densitometric
data was corrected by subtraction of the relative amount of MBP–
Pf332-F7 pelleted in the absence of F-actin and graphed. Using
regression analysis of the saturation curve data, the half saturation
concentration (Kd) was determined to be Kd=0.60 µM.
3.5. Pf332 does not bind to spectrin
To determine whether Pf332 bound to spectrin, we performed
binding assays between the MBP–Pf332-F19 and puriﬁed spectrin
Fig. 3. Finer mapping of residues in Pf332-F19 that bind to the RBCmembrane skeleton. A. Schematic representation of full length Pf332 protein showing the relative locations on the
twenty fragments investigated. To further deﬁne the binding residues contained within the 260 residue -F19 region, three smaller non-overlapping sub-fragments (-F19a, -F19b and
-F19c) were expressed and puriﬁed as MBP fusion proteins. B. Puriﬁed MBP–Pf332 F19 sub-fragment fusion proteins. 2 µg (total protein) of each puriﬁed protein was resolved by
SDS-PAGE before staining with Coomassie Brilliant Blue. C. Each of the MBP–Pf332 F19 sub-fragment fusion proteins (50 ng total protein) was immunoblotted with anti-MBP
antiserum to conﬁrm the presence of the N-terminal MBP tag and demonstrate the apparent molecular mass of each protein when immunoblotted. D. The TX100 soluble (S) and
insoluble (I) fractions of lysed and resealed RBCs that had been incubated with 5 µM fusion protein were resolved by SDS-PAGE and immunoblotted with anti-MBP antiserum. MBP–
Pf332-F19, and its sub-fragment proteins -F19a and -F19c were both detected in the Tx100 soluble and insoluble fractions, whereas the intervening sub-fragment -F19b was not.
Neither MBP nor MBP–PfEMP3-F5 was detected in the insoluble fractions, whereas MBP–PfEMP3-F1a was. Together, these data map amembrane skeleton binding region of Pf332 to
the 86 residues of -F19a. These data also suggest the presence of other residues within the downstream 72 residues of -F19c that may contribute to the overall protein interaction of
Pf332 with the membrane skeleton. E. A saturation of binding curve was constructed from the densitometric data obtained from a representative IOV binding assay using serial
dilutions of MBP–Pf332-F19 protein (titrated from 5.0 to 0.0 µM; panel below the graph). The half saturation concentration (Kd) was determined to be Kd=0.40 µM.
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bound to spectrin at levels comparable to the negative interaction
control BSA. A spectrin-binding positive control interaction was
simultaneously performed using MBP fused to the spectrin-binding
region of PfEMP3 (MBP–PfEMP3-F1a.1; [15]). MBP–PfEMP3-F1a.1
bound to spectrin but not to BSA. Taken together with the actin
pelleting experiments above, it appears that Pf332 binds to the RBC
membrane skeleton via speciﬁc interactions with actin but not
spectrin (data not shown).3.6. PfEMP3-F1a and Pf332-F19 bind to different regions of F-actin
To determine if either of the actin-binding regions that we have
identiﬁed in PfEMP3 [15] or Pf332were able to bind the same residues
in actin, we performed inhibition of binding to actin co-sedimentation
assays. In these assays, we added F-actin (5 μM) to either MBP–
PfEMP3-F1a (5 μM) or MBP–Pf332-F19 (5 μM), and then added the
other protein (titrated from 20 μM to 0.0 μM). A representative
experiment is shown in Fig. 5. Neither increasing concentrations of
Fig. 4. Pf332-F19 binding to actin is saturable and speciﬁc. A. Actin co-sedimentation assays were performed using polymerised F-actin. Constant concentrations of F-actin (5 µM)
were incubated with titrated serial dilutions of MBP–Pf332-F19 and centrifuged. The pellet and supernatant fractions were analysed by immunoblotting with anti-MBP and anti-
actin antibodies and subsequent densitometry. MBP–Pf332-F19 pelleted with F-actin, whereas the non-binding MBP and MBP–Pf332-F7 proteins remained in the supernatant. B. A
saturation of binding curve was constructed from the densitometric data obtained from a representative actin co-sedimentation assay using MBP–Pf332-F19 protein (panel A). The
half saturation concentration (Kd) was determined to be Kd=0.60 µM.
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of the other protein to F-actin under these assay conditions. In both
instances, only residual levels of the negative interaction control
proteins MBP (5.0 μM), MBP–Pf332-F7 (5.0 μM) and MBP–Pf332-F5
(5.0 μM) pelleted with F-actin. The positive interaction controls MBP–
PfEMP3-F1a (5.0 μM) and MBP–Pf332-F19 (5.0 μM) each pelleted
with F-actin as expected (Fig. 5). Additionally, we also conducted
inhibition of co-sedimentation assays in which F-actin (5 μM) was
pre-incubated with either MBP–PfEMP3-F1a (5 μM) or MBP–Pf332-
F19 (5 μM) for 1 h prior to the addition of the other protein (titrated
from 20 μM to 0.0 μM) and further incubation (data not shown). No
discernable difference was observed in experimental outcome
resulting from assays in which F-actin had or had not been pre-
incubated with a binding partner prior to the addition of serially
titrated third protein (data not shown). Taken together, these data
demonstrate that PfEMP3-F1a and Pf332-F19 are not able to displace
each other from binding to actin, and thus bind to physically distinct
regions within actin.
4. Discussion
Pf332 is synthesized by the intracellular malaria parasite and
exported to the RBC via MCs where it associates with the RBC
membrane skeleton [25,26]. The current membrane topology of Pf332
predicts that the N-terminal 540 residue region of Pf332 (encoded by
exon 1; Fig. 1A) is located in either in the lumen of an organelle (theMC) or extracellularly exposed on the IRBC [30]. This prediction seems
reasonable as this domain contains a Duffy Binding-Like (DBL)
domain which is rich in cysteine residues that are likely to form
numerous disulphide bonds, which can only occur in an oxidizing
environment found inside trafﬁcking organelles or extracellularly.
Therefore, the sequences encoded by exon one of pf332 would not be
present within the same biological compartment as the RBC
membrane skeleton. Hence, our protein interaction studies focused
speciﬁcally upon the residues downstream of the transmembrane
spanning domain (Fig. 1A) that are encoded by the second exon of the
pf332 gene and are predicted to reside entirely within the RBC cytosol
[30].
Here, using two independent in vitro interaction methods that
utilize properly conformed RBC membrane skeletons, we have
mapped the membrane skeleton binding domain of Pf332 to a 260
residue region located proximal to its C-terminus. Actin co-sedimen-
tation assays further demonstrated that this 260 residue region of
Pf332 binds to actin in a speciﬁc and saturable manner with moderate
afﬁnity. Additional mapping studies reﬁned the binding region
predominantly to an 86 residue region encompassed by the -F19a
sub-region of Pf332 (residues 5155–5201), although other residues
(located in -F18 and -F19c) seem to provide some weaker contribu-
tion to the overall interaction. The presence of binding sequences
encoded in -F19b however, cannot be ruled out because despite
numerous attempts of optimise the yield of -F19b full length fusion
protein, the relative quality of the -F19b used was poor when
Fig. 5. PfEMP3-F1a and Pf332-F19 bind to different regions of F-actin. Inhibition of binding to actin co-sedimentation assays were performed to determine if MBP–PfEMP3-F1a or
MBP–Pf332-F19 bound to the same residues in actin. In these assays, F-actin (5 µM)was added to either MBP–PfEMP3-F1a (5 µM) orMBP–Pf332-F19 (5 µM) before the other protein
(titrated from 5.0 to 0.0 µM) was added and the mixture subsequently incubated. Resultant pellet and supernatant fractions were immunoblotted using either anti-MBP antiserum
or monoclonal anti-actin antibodies. A. Constant concentrations of F-actin (5 µM) and MBP–PfEMP3-F1a (5 µM; ∼60 kDa) were incubated with titrated serial dilutions of MBP–
Pf332-F19 (5.0 to 0.0 µM; ∼85 kDa) and centrifuged. No inhibition of MBP–PfEMP3-F1a binding to F-actin in the presence of increasing concentrations of MBP–Pf332-F19 (0.0 to
5.0 µM) was detected in the pelleted fractions. Only residual levels of the negative interaction control proteins MBP (5.0 µM), MBP–Pf332-F7 (5.0 µM), MBP–Pf332-F5 (5.0 µM)
pelleted with F-actin. The positive interaction controls MBP–PfEMP3-F1a (5.0 µM) and MBP–Pf332-F19 (5.0 µM) each pelleting separately with F-actin were included. B. Constant
concentrations of F-actin (5 µM) and MBP–Pf332-F19 (5 µM; ∼85 kDa) were incubated with titrated serial dilutions of MBP–PfEMP3-F1a (5.0 to 0.0 µM; ∼60 kDa) and centrifuged.
No inhibition of MBP–Pf332-F19 binding to F-actin in the presence of increasing concentrations of MBP–PfEMP3-F1a (5.0 to 0.0 µM) was detected in the pelleted fractions. As above,
only residual levels of the negative interaction control proteins MBP (5.0 µM), MBP–Pf332-F7 (5.0 µM), MBP–Pf332-F5 (5.0 µM) pelleted with F-actin. The positive interaction
controls MBP–PfEMP3-F1a (5.0 µM) and MBP–Pf332-F19 (5.0 µM) each pelleting separately with F-actin were included.
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to deﬁned binding regions that also contribute to overall interactions
between RBC membrane skeleton and parasite proteins have been
previously described for other P. falciparum proteins, including MESA
and PfEMP3 [15,38]. Additionally, since comparatively more of the
input -F19a protein remained in the insoluble fraction than -F19c
(Fig. 3C), it is possible that -F19a may possess higher afﬁnity for its
binding partner in the RBCmembrane skeleton than -F19c, but further
experimentation would be required to conﬁrm this suggestion.
Further, calculation of the pI of actin and each MBP–Pf332 fusion
protein (Table 1 and footnotes) indicates that it is unlikely that
electrostatic forces are contributing signiﬁcantly to any of thedetermined actin-binding afﬁnities however, this phenomenon
cannot be excluded for Pf332 binding to RBC membrane skeletons
due to the heterogeneous nature of the proteins present in that
binding substrate.
The moderate afﬁnity half saturation concentrations (Kd) estimat-
ed for the 260 residue -F19 region binding to the RBC membrane
skeleton or to puriﬁed actin are similar to those observed for other
protein interactions that occur at the RBC membrane skeleton of
uninfected or infected RBCs. In uninfected RBCs, the binding afﬁnities
of several protein interactions have been quantitated in vitro,
including 4.1R binding to p55 (Kd(kin)=1×10−7 M; [39]), protein
4.2 binding to band 3 (Kd=2–8×10−7 M; [40]) and protein 4.2
870 K.L. Waller et al. / Biochimica et Biophysica Acta 1798 (2010) 861–871binding to ankyrin (Kd=1–3.5×10−7 M; [40]). These moderate
afﬁnities are also typical of those seen for malaria proteins binding
at the membrane skeleton to host or malaria proteins in vitro. These
include MESA binding to 4.1R (Kd(kin)=1.3×10−7 M; [14]), KAHRP
binding to PfEMP1 (Kd(kin)=1×10−7 M; [22] and PfEMP3 binding to
spectrin (Kd(kin)=3.8×10−7 M; [15]). The similarity between the
values determined for interactions between Pf332 and the membrane
skeleton or puriﬁed actin is consistent with the proposition that actin
may be the only protein at the IRBC membrane skeleton with
signiﬁcant ability to bind Pf332. We certainly cannot ﬁnd any
evidence for interaction of Pf332 with spectrin, but of course
interaction assays using other puriﬁed native or recombinant RBC
membrane skeleton proteins would be required to deﬁnitively
exclude other partners. Although we cannot deﬁnitively exclude the
possibility that the actin-binding afﬁnity determined herein (using
muscle actin) may be different to that derived using RBC actin,
we believe that any differences are most likely to be subtle at
best given the concordance between the Pf332 binding afﬁnities
estimated for RBC membrane skeletons (Kd=0.40 µM) and actin
(Kd=0.60 µM).
In a previous study, we identiﬁed a 14 residue region of the
parasite protein PfEMP3 that binds to both spectrin and actin [15].
Here, we used inhibition co-sedimentation assays to investigate
whether the 260 residue actin-binding region of Pf332 was able to
bind the same region in actin as PfEMP3. In these assays, F-actin was
pre-incubated with either MBP–PfEMP3-F1a (which possesses the 14
residue actin-binding region) or MBP–Pf332-F19 before the addition
of the other protein in a serially titrated fashion. Regardless of which
protein was pre-incubated with F-actin, in each case the titrated
protein was not able to discernibly inhibit the interaction of the pre-
incubated protein with F-actin. Thus, from these experiments we
were able to conclude that the proteins PfEMP3 and Pf332 most likely
bind to physically separate residues in actin.
Pf322 has recently been implicated in both decreasing RBC
membrane rigidity and in assisting trafﬁcking of PfEMP1 to the IRBC
membrane surface [31,32]. These studies showed that sequences
located in the N-terminal region of Pf332were important for adhesion
and PfEMP1 trafﬁcking, whereas sequences in the C-terminal domain
of Pf332were important in alteredmembrane rigidity [31]. The region
we have identiﬁed as the Pf332 actin-binding region (residues 5115–
5201) is deleted from these C-terminally truncated Pf332 mutant
parasites. Together these data suggest that binding of Pf332 to
membrane skeleton actin is required for modulating the structural
andmechanical properties of the RBCmembrane skeleton. In a normal
membrane skeleton, interactions between αβ-spectrin heterodimers,
actin and 4.1R facilitate the formation of a ﬂexible lattice-like skele-
ton that is able to withstand repeated deformation in the micro-
vasculature. Both 4.1R and actin bind to spectrin via sequences in the
N-terminal 301 residue region of β-spectrin which encompasses the
calponin homology domains (CH1 and CH2) [41]. Each of the CH1 and
CH2 domains possess an actin and a 4.1R binding site. Thus, given that
actin interacts with spectrin, and that the binding of 4.1R potentiates
the interaction between spectrin and actin [42,43], it is likely that the
binding of Pf332 to actin reduces actin's binding afﬁnity for spectrin
and 4.1R, resulting in suppression of membrane rigidity in the IRBC
membrane skeleton. Additionally, binding of Pf332 to actin may also
modulate actin's interactions with other membrane skeleton proteins
including tropomyosin [44], adducin [45] and protein 4.9 (dematin)
[46], however, further binding studies using puriﬁed native or
recombinant RBC membrane skeleton proteins would be required to
fully deﬁne these possible interactions and their effects on the
membrane skeleton. The continued investigation of Pf332's interac-
tions and the interactions of other parasite proteins at the IRBC
membrane skeleton will ultimately expand our understanding of
parasite-induced modiﬁcations that contribute signiﬁcantly to the
severe pathophysiology of P. falciparum malaria.Acknowledgements
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